Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-31 and Seasonal Influenza Vaccine Co-administration in Adults >= 50 Years
NCT07365826Phase 3Active, not recruiting
- Sponsor
- Vaxcyte
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of VAX-31 in pneumococcal disease, sponsored by Vaxcyte. Started Jan 2026; status: active, not recruiting.
02
Drugs
VAX-31
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07365826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365826.